Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2012 Mar 28;44(4):359-60.
doi: 10.1038/ng.2236.

The role of ATM in response to metformin treatment and activation of AMPK

Sook Wah Yee, Ligong Chen, Kathleen M Giacomini
Comment

The role of ATM in response to metformin treatment and activation of AMPK

Sook Wah Yee et al. Nat Genet. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Cellular metformin uptake in H4IIE and HEK293 cells. (a,b) The effect of KU-55933 and OCT inhibitors on the uptake of metformin in H4IIE cells (a) and HEK293 cells stably expressing empty vector or human OCT1 (b). Cells were pretreated with DMSO or KU-55933 or other OCT1 inhibitors for 30 min and then treated with various concentrations of metformin (with 10 mM [14C]-metformin) for 1 h. The amount of [14C]-metformin in cells was measured. All the compounds except para-aminohippuric acid (PAH; a negative control) significantly inhibited metformin uptake (***P < 0.001, **P < 0.01, *P < 0.05; unpaired Student’s t test) compared to cells preincubated with DMSO alone. All data are expressed as mean ± s.d. from two independent uptake experiments. HEK293 cells stably expressing human OCT1 showed greater OCT1 expression on the plasma membrane compared to cells expressing empty vector.
See this image and copyright information in PMC

Comment in

Comment on

  • Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes.
    GoDARTS and UKPDS Diabetes Pharmacogenetics Study Group; Wellcome Trust Case Control Consortium 2; Zhou K, Bellenguez C, Spencer CC, Bennett AJ, Coleman RL, Tavendale R, Hawley SA, Donnelly LA, Schofield C, Groves CJ, Burch L, Carr F, Strange A, Freeman C, Blackwell JM, Bramon E, Brown MA, Casas JP, Corvin A, Craddock N, Deloukas P, Dronov S, Duncanson A, Edkins S, Gray E, Hunt S, Jankowski J, Langford C, Markus HS, Mathew CG, Plomin R, Rautanen A, Sawcer SJ, Samani NJ, Trembath R, Viswanathan AC, Wood NW; MAGIC investigators; Harries LW, Hattersley AT, Doney AS, Colhoun H, Morris AD, Sutherland C, Hardie DG, Peltonen L, McCarthy MI, Holman RR, Palmer CN, Donnelly P, Pearson ER. GoDARTS and UKPDS Diabetes Pharmacogenetics Study Group, et al. Nat Genet. 2011 Feb;43(2):117-20. doi: 10.1038/ng.735. Epub 2010 Dec 26. Nat Genet. 2011. PMID: 21186350 Free PMC article.

References

    1. The GoDARTS and UKPDS Diabetes Pharmacogenetics Study Group & The Wellcome Trust Case Control Consortium 2. Nat. Genet. 2011;43:117–120. - PubMed
    1. Sanli T, et al. Int. J. Radiat. Oncol. Biol. Phys. 2010;78:221–229. - PubMed
    1. Sun Y, Connors KE, Yang DQ. Mol. Cell. Biochem. 2007;306:239–245. - PubMed
    1. Fu X, Wan S, Lyu YL, Liu LF, Qi H. PLoS One. 2008;3:e2009. - PMC - PubMed
    1. Shu Y, et al. J. Clin. Invest. 2007;117:1422–1431. - PMC - PubMed

MeSH terms